CBL Antikörper

Produktnummer ABIN968993

Für dieses Produkt sind 3+ Publikationen verfügbar. Der Maus-Monoklonal Anti-CBL-Antikörper wurde für WB, ELISA, IHC, ICC und FACS validiert. Er ist geeignet zum Nachweis von CBL in Proben aus Human, Maus und Ratte. }

Kurzübersicht für CBL Antikörper (ABIN968993)

Target: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Reaktivität: Human, Maus, Ratte

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CBL Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FACS)

Klon: 3B12

Produktdetails anti-CBL Antikörper

Verwendungszweck: C-CBL Antibody

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of human C-CBL expressed in E. Coli.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise:

ELISA: 1/10000

FCM: 1/200 - 1/400

ICC: 1/200 - 1/1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-CBL Antikörper (ABIN968993)

Sproul, Xu, Wilhelm, Gire, Greene: "Cbl negatively regulates JNK activation and cell death." in: Cell research, Vol. 19, Issue 8, pp. 950-61, (2009) (PubMed).

Sanada, Suzuki, Shih, Otsu, Kato, Yamazaki, Tamura, Honda, Sakata-Yanagimoto, Kumano, Oda, Yamagata, Takita, Gotoh, Nakazaki, Kawamata, Onodera, Nobuyoshi, Hayashi, Harada, Kurokawa, Chiba, Mori et al.: "Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. ..." in: Nature, Vol. 460, Issue 7257, pp. 904-8, (2009) (PubMed).

Loh, Sakai, Flotho, Kang, Fliegauf, Archambeault, Mullighan, Chen, Bergstraesser, Bueso-Ramos, Emanuel, Hasle, Issa, van den Heuvel-Eibrink, Locatelli, Stary, Trebo, Wlodarski, Zecca, Shannon et al.: "Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. ..." in: Blood, Vol. 114, Issue 9, pp. 1859-63, (2009) (PubMed).

Details zu CBL

Target: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Andere Bezeichnung: C-CBL

Hintergrund: The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation.

Molekulargewicht: 120 kDa

Gen-ID: 867

UniProt: P22681

Pathways: T-Zell Rezeptor Signalweg, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals